YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
(RTTNews) - The following biotech stocks reached 52-week highs on July 24, 2026, driven by key catalysts like the upcoming release of quarterly reports or various regulatory milestones. Inhibikase Therapeutics Inc. (IKT) Inhikibase Therape…
[Abstract stock market chart with multicolored candlestick patterns and numeric overlays on a dark background. Concept for trading, investing, cryptocurrency markets and digital economy presentations.] vadishzainer/iStock via Getty Images…
(RTTNews) - These biotech stocks touched a 52-week high on July 14, 2026, attributable to key catalysts like announced offerings to increase capital and the expansion of business ventures. The Oncology Institute Inc. (TOI) The Oncology Ins…
WILMINGTON, Del., April 03, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 685,718 sh…
The stock market has been treading water so far this year, with the S&P 500 up roughly 1% while the Nasdaq has slipped 1.5%. Tech stocks have struggled to regain last year’s momentum as investors reassess the durability of AI-driven spendi…
Clinical-stage pharmaceutical company Inhibikase Therapeutics (IKT [https://seekingalpha.com/symbol/IKT]) announced the pricing [https://seekingalpha.com/pr/20316733-inhibikase-therapeutics-announces-pricing-of-100-million-public-offering-…
WILMINGTON, Del., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hyperte…
* Inhibikase Therapeutics (NASDAQ:IKT [https://seekingalpha.com/symbol/IKT]) announced [https://seekingalpha.com/pr/20316495-inhibikase-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre-funded] on Thursday that it has…
BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hyper…
Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (…
* Inhibikase Therapeutics press release [https://seekingalpha.com/pr/20308610-inhibikase-therapeutics-announces-third-quarter-2025-financial-results-and-highlights-recent] (IKT [https://seekingalpha.com/symbol/IKT]): Q3 GAAP EPS of -$0.13.…
BOSTON and ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases…
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT VTAK [https://w…
BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases…
Inhibikase Therapeutics, Inc. (NASDAQ:IKT), a pharmaceutical company currently trading near $1.95 and showing a strong 17.47% gain over the past week, held its 2025 Annual Meeting of Stockholders on Friday. According to a statement based o…
Ludwig Enterprises, Inc. (OTC:LUDG) announced the appointment of Garth Lees-Rolfe as an independent director, effective Monday. The decision was made by the company’s board of directors and was disclosed in a press release statement based…
* Inhibikase Therapeutics (NASDAQ:IKT [https://seekingalpha.com/symbol/IKT]) filed $300M mixed securities shelf. * Filing [https://seekingalpha.com/filing/10116244] MORE ON INHIBIKASE THERAPEUTICS * Inhibikase Therapeutics: A Hold With Unc…
BOSTON and ATLANTA, May 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonar…
BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial…
BOSTON and ATLANTA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Par…
This release corrects and replaces the headline in the release that was disseminated on November 7, 2023. The reason for this correction is to fix the title which previously stated, "second quarter" rather than "third quarter." BOSTON and…
BOSTON and ATLANTA, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of…
BOSTON and ATLANTA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Par…
BOSTON and ATLANTA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Par…
BOSTON and ATLANTA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Pa…
The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more. Here's The Petri Dish, a roundup of news t…
BOSTON and ATLANTA, May 9, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, to…
(UP 5.5% AS REPORTED, UP 2.2% AT CONSTANT EXCHANGE RATES) Q1 2022 ESSENTIALS SALES: €77M (UP 8.1% AS REPORTED, UP 5.5 AT CONSTANT EXCHANGE RATES) LURE, France, April 13, 2022--(BUSINESS WIRE)--Regulatory News: Vetoquinol (Paris:VETO): Matt…
U.S. stock futures were mixed on Wednesday ahead of the Federal Reserve’s policy decision, following its Federal Open Market Committee (FOMC) two-day policy meeting. Notably, investors await data for May related to housing starts and permi…
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 25) Cellect Biotechnology Ltd. (NASDAQ: APOP) ( announced a reverse merger) GenMark Diagnostics…
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 24) F-star Therapeutics, Inc. (NASDAQ: FSTX) IDEAYA Biosciences, Inc. (NASDAQ: IDYA) Orphazyme…
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 4) AtriCure, Inc. (NASDAQ: ATRC) Five Prime Therapeutics, Inc. (NASDAQ: FPRX) - announced a dea…
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 4) AtriCure, Inc. (NASDAQ: ATRC) Five Prime Therapeutics, Inc. (NASDAQ: FPRX) - announced a dea…
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 3) Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) Bausch Health Companies Inc. (NYSE: BHC) ENDRA Li…
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 3) Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) Bausch Health Companies Inc. (NYSE: BHC) ENDRA Li…
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 29) ABIOMED, Inc. (NASDAQ: ABMD) Apellis Pharmaceuticals Inc (NASDAQ: APLS) Atea Pharmaceuticals…